NCT00705575 - Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension | Biotech Hunter

Enrollment

688

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Hypertension

Interventions

DRUG

Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)

During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.

DRUG

Aliskiren (300 mg)

During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.

Trial Locations (8)

Investigative Site, East Hanover

Investigative Site, Buenos Aires

Investigative Site, Quito

Investigative Site, Berlin

Investigative Site, Guatemala City

Investigative Site, Rome

Investigative Site, Basel

Investigative Site, Ankara